BRPI0515334A - uso de um antìgeno de plasmodium - Google Patents

uso de um antìgeno de plasmodium

Info

Publication number
BRPI0515334A
BRPI0515334A BRPI0515334-4A BRPI0515334A BRPI0515334A BR PI0515334 A BRPI0515334 A BR PI0515334A BR PI0515334 A BRPI0515334 A BR PI0515334A BR PI0515334 A BRPI0515334 A BR PI0515334A
Authority
BR
Brazil
Prior art keywords
antigen
plasmodium antigen
relates
malaria
immunize against
Prior art date
Application number
BRPI0515334-4A
Other languages
English (en)
Inventor
Joseph D Cohen
Nadia Gabriela Tornieporth
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33306702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0515334(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0515334A publication Critical patent/BRPI0515334A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

USO DE UM ANTìGENO DE PLASMODIUM A presente invenção refere-se a um novo uso de um antígeno da malária, para imunizar contra doença malárica. A invenção refere-se, em particular, ao uso de antígenos de esporozoíta, em particular proteína de circunsporozoíta (CS) ou seus fragmentos, para imunizar contra doença malárica severa.
BRPI0515334-4A 2004-09-16 2005-09-14 uso de um antìgeno de plasmodium BRPI0515334A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0420634A GB0420634D0 (en) 2004-09-16 2004-09-16 Vaccines
PCT/EP2005/009995 WO2006029887A2 (en) 2004-09-16 2005-09-14 Vaccines comprising plasmodium antigens

Publications (1)

Publication Number Publication Date
BRPI0515334A true BRPI0515334A (pt) 2008-07-22

Family

ID=33306702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515334-4A BRPI0515334A (pt) 2004-09-16 2005-09-14 uso de um antìgeno de plasmodium

Country Status (18)

Country Link
US (1) US20080102091A1 (pt)
EP (1) EP1791558A2 (pt)
JP (2) JP5670611B2 (pt)
KR (1) KR101362097B1 (pt)
CN (2) CN104027795A (pt)
AR (1) AR051023A1 (pt)
AU (1) AU2005284223B2 (pt)
BR (1) BRPI0515334A (pt)
CA (1) CA2579527C (pt)
GB (1) GB0420634D0 (pt)
IL (1) IL181733A0 (pt)
MA (1) MA28885B1 (pt)
MX (1) MX2007003160A (pt)
NO (1) NO20071523L (pt)
RU (1) RU2423994C2 (pt)
SG (2) SG193159A1 (pt)
TW (1) TW200621287A (pt)
WO (1) WO2006029887A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2794647B2 (ja) 1992-04-17 1998-09-10 株式会社間組 ダム構造とダムの築造法
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
JP5222289B2 (ja) 2006-07-18 2013-06-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
SI2097102T1 (sl) 2006-09-07 2012-09-28 Glaxosmithkline Biolog Sa Kombinirano cepivo, ki ima zmanjšane količine antigena za poliovirus
CN103550764A (zh) * 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
CL2008002361A1 (es) * 2007-08-13 2009-08-07 Glaxosmithkline Biologicals Sa Uso de un antigeno derivado de la proteina circumesporozoito (cs) de plasmodium falciparum que se expresa en la etapa preeritrocitica de la infeccion por malaria para tratar bebes contra la malaria.
WO2010108177A2 (en) * 2009-03-20 2010-09-23 University Of South Florida A method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target
US20120244178A1 (en) * 2011-03-25 2012-09-27 Denise Doolan Plasmodium falciparum antigens
US9241988B2 (en) * 2012-04-12 2016-01-26 Avanti Polar Lipids, Inc. Disaccharide synthetic lipid compounds and uses thereof
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US10058603B2 (en) 2013-03-15 2018-08-28 Glaxosmithkline Biologicals S.A. Vaccine
GB201416773D0 (en) * 2014-09-23 2014-11-05 Glaxosmithkline Biolog S A And Chancellor Masters And Scolars Of The The University Of Oxford Novel Methods For Including An Imune Response
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
WO2017048689A1 (en) * 2015-09-16 2017-03-23 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
WO2020221451A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies binding to plasmodium circumsporozoite protein and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3954643B2 (ja) * 1991-11-16 2007-08-08 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質
DE69313134T2 (de) * 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
EP1423405A4 (en) * 2001-03-26 2005-01-05 Us Army PROTEIN AMA-1 FROM PLASMODIUM FALCIPARUM AND USES THEREOF
AU2003291476A1 (en) * 2002-11-12 2004-06-03 Walter Reed Army Institute Of Research Expression, purification and uses of a plasmodium falciparum liver stage antigen 1 polypeptide
EP1692285B1 (en) * 2003-08-15 2012-04-11 Commonwealth Scientific and Industrial Research Organisation Methods and means for altering fiber characteristics in fiber-producing plants

Also Published As

Publication number Publication date
WO2006029887A3 (en) 2006-05-11
JP5670611B2 (ja) 2015-02-18
AU2005284223B2 (en) 2011-12-15
MX2007003160A (es) 2007-10-23
CN101056653A (zh) 2007-10-17
RU2423994C2 (ru) 2011-07-20
NO20071523L (no) 2007-03-28
KR101362097B1 (ko) 2014-02-21
EP1791558A2 (en) 2007-06-06
WO2006029887A2 (en) 2006-03-23
SG159520A1 (en) 2010-03-30
CN104027795A (zh) 2014-09-10
KR20070052342A (ko) 2007-05-21
JP5632404B2 (ja) 2014-11-26
SG193159A1 (en) 2013-09-30
RU2007109608A (ru) 2008-10-27
JP2012116849A (ja) 2012-06-21
CA2579527A1 (en) 2006-03-23
IL181733A0 (en) 2007-07-04
JP2008513400A (ja) 2008-05-01
US20080102091A1 (en) 2008-05-01
AU2005284223A1 (en) 2006-03-23
AR051023A1 (es) 2006-12-13
CA2579527C (en) 2016-06-21
TW200621287A (en) 2006-07-01
MA28885B1 (fr) 2007-09-03
GB0420634D0 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
NO20071523L (no) Vaksiner
CR11307A (es) Vacunas
UA93508C2 (en) Anti-malaria vaccine
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CR10101A (es) Nueva composición
WO2004063963A3 (en) Novel proteins with altered immunogenicity
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
UY26555A1 (es) Composición farmacéutica para modulación inmunológica y preparación de vacunas
WO2007120673A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2006041933A3 (en) Improved vaccines
WO2009125231A3 (en) Anti-atheroma vaccine
WO2008048945A3 (en) Conjugates of plasmodium falciparum surface proteins as malaria vaccines
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
ATE485833T1 (de) Pharmazeutische zusammensetzungen, die die immunogenität von schwach immunogenen antigenen fördern
DE602006013428D1 (de) Chimaere rekombinante antigene von toxoplasma gondii
WO2003016354A3 (en) Recombinant anti-plasmodium falciparum antibodies
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
WO2006124712A3 (en) A method for improving the immunogenicity of plasmodium antigens
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
WO2007062819A3 (en) Multimeric complexes of antigens and an adjuvant
WO2008034121A3 (en) Parasite vaccine
UY31510A1 (es) Vacunacontra la malaria, especifica para el parasito plasmodium falciparum
WO2005014654A3 (en) Product comprising a c4bp core protein and a monomeric antigen, and its use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL